AbbVie's strong entrenchment in the aesthetics business (gained through the Allergan acquisition) sets up very long product cycles for several key assets like Botox based on strong brand power and ...

The licensing deal comes as AbbVie is weathering the impact of biosimilar competition to Humira (adalimumab), its big-selling immunology and inflammation brand used to treat a host of diseases ...

There are many other products AbbVie can count on, from migraine medicine Qulipta to its Botox franchise. And, of course, investors can expect the company to earn brand-new approvals, be it thanks to ...

AbbVie has entered a partnership and option-to-license agreement with Xilio Therapeutics to develop new tumour-activated, ...

AbbVie (NYSE: ABBV) closed out a pivotal 2024 with an excellent fourth-quarter earnings report. For the period ended Dec. 31, the biopharmaceuticals giant delivered 6% sales growth and $2.12 in ...

make sure to grab a free copy of our brand-new “The Next NVIDIA” report. It features a software stock we’re confident has 10X potential. AbbVie has been in a rut since last November when ...

On CNBC's “Mad Money Lightning Round,” Jim Cramer recommended buying AbbVie Inc. (NYSE:ABBV), saying it's “just a gem” and a “winner.”  He added, “I can't believe the stock dropped so much.” ...